文献速递浆细胞疾病

抑制IL-10R可重编程肿瘤相关巨噬细胞并逆转多发性骨髓瘤耐药

IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma.
PubMed 文献 · Leukemia · 2024-08-30

研究探讨IL-10在多发性骨髓瘤(MM)肿瘤相关巨噬细胞(TAM)发育中的作用及靶向IL-10/IL-10R/STAT3信号的治疗潜力。结果显示MM骨髓中IL-10过表达并介导TAM的M2样极化,TAM促进MM增殖和耐药;阻断IL-10R或降解STAT3可阻止M2极化、抑制TAM诱导的增殖并逆转耐药。作者认为该轴抑制是具单药疗效且可与免疫调节药物联合的新策略,但需未来研究在MM患者中评估。

要点

  • MM骨髓中IL-10过表达,介导TAM的M2样极化。
  • TAM促进MM增殖和耐药,体外和体内均如此。
  • 阻断IL-10/IL-10R/STAT3轴可阻止M2极化并逆转耐药。

核心结论

  • 抑制IL-10/IL-10R/STAT3轴是具单药疗效的新治疗策略,可进一步与免疫调节药物等现有抗MM治疗联合以克服耐药。
  • 未来需开展研究评估该疗法在MM患者中的潜力。

研究设计与样本

  • 研究采用患者骨髓样本、体外3D共培养和小鼠模型,探讨IL-10在MM TAM发育中的作用及IL-10/IL-10R/STAT3信号抑制的治疗应用。

主要发现

  • IL-10在MM骨髓中过表达,并在患者骨髓、体外3D共培养和小鼠模型中介导TAM的M2样极化。
  • TAM在体外和体内均促进MM增殖和耐药。
  • 使用阻断性IL-10R单克隆抗体和STAT3蛋白降解剂/PROTAC抑制IL-10/IL-10R/STAT3轴,在体外和体内阻止TAM的M2极化及TAM诱导的MM增殖,并使MM重新对治疗敏感。

临床怎么用

  • 作者认为抑制IL-10/IL-10R/STAT3轴是具单药疗效的新治疗策略,可进一步与免疫调节药物等现有抗MM治疗联合以克服耐药。
  • 作者提出未来需开展研究评估该疗法在MM患者中的潜力。

局限性

  • 未来需开展研究评估该疗法在MM患者中的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is the cancer of plasma cells within the bone marrow and remains incurable. Tumor-associated macrophages (TAMs) within the tumor microenvironment often display a pro-tumor phenotype and correlate with tumor proliferation, survival, and therapy resistance. IL-10 is a key immunosuppressive cytokine that leads to recruitment and development of TAMs. In this study, we investigated the role of IL-10 in MM TAM development as well as the therapeutic application of IL-10/IL-10R/STAT3 signaling inhibition. We demonstrated that IL-10 is overexpressed in MM BM and mediates M2-like polarization of TAMs in patient BM, 3D co-cultures in vitro, and mouse models. In turn, TAMs promote MM proliferation and drug resistance, both in vitro and in vivo. Moreover, inhibition of IL-10/IL-10R/STAT3 axis using a blocking IL-10R monoclonal antibody and STAT3 protein degrader/PROTAC prevented M2 polarization of TAMs and the consequent TAM-induced proliferation of MM, and re-sensitized MM to therapy, in vitro and in vivo. Therefore, our findings suggest that inhibition of IL-10/IL-10R/STAT3 axis is a novel therapeutic strategy with monotherapy efficacy and can be further combined with current anti-MM therapy, such as immunomodulatory drugs, to overcome drug resistance. Future investigation is warranted to evaluate the potential of such therapy in MM patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Sun J, Corradini S, Azab F, et al. IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma. Leukemia. 2024. PMID: 39215060. doi:10.1038/s41375-024-02391-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。